BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from human gastric juice that has shown consistent mucosal healing, anti-inflammatory, and tissue repair effects across dozens of animal studies. For Crohn's disease specifically, the preclinical evidence is relevant: BPC-157 accelerates healing in TNBS colitis models (the closest animal analog to Crohn's transmural inflammation), promotes fistula closure, and protects against NSAID-induced intestinal damage. No human clinical trial has been conducted. This is Grade C evidence. This guide covers the Crohn's-specific data, distinguishing it from the general BPC-157 gut healing guide, and addresses drug interactions with IBD medications that no other source covers honestly.
How BPC-157 Works in the Gut
The BPC-157 gut healing guide covers the full mechanism in detail. Here is a summary focused on the pathways most relevant to Crohn's disease.
VEGF and Angiogenesis
BPC-157 upregulates vascular endothelial growth factor (VEGF), promoting the formation of new blood vessels at sites of tissue damage. In Crohn's, the inflammatory process damages the mucosal microvasculature. Ischemia (inadequate blood flow) in the intestinal wall contributes to the characteristic deep ulcerations and transmural inflammation that distinguish Crohn's from ulcerative colitis. By restoring blood supply to damaged tissue, BPC-157 supports the delivery of oxygen, nutrients, and immune cells necessary for repair.
Sikiric et al. documented this mechanism across multiple injury models. The angiogenic effect is not a generic growth stimulus. BPC-157 appears to restore normal vascular patterns rather than promoting pathological angiogenesis, though this distinction has only been characterized in animal tissue.
Tight Junction Restoration
Intestinal permeability ("leaky gut") is a documented feature of Crohn's disease. Fasano et al. established the role of zonulin-mediated tight junction disassembly in intestinal permeability and its connection to autoimmune disease. In Crohn's patients, increased permeability allows luminal contents (bacteria, dietary antigens) to contact the submucosa, driving the inflammatory cascade.
BPC-157 promotes tight junction protein expression in animal models, including claudin-3, occludin, and ZO-1. By restoring the physical barrier between the intestinal lumen and the lamina propria, BPC-157 addresses one of the upstream drivers of Crohn's inflammation rather than simply suppressing the downstream immune response.
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system in a context-dependent manner. In situations of excessive NO production (as occurs in active Crohn's inflammation, where inducible nitric oxide synthase is upregulated), BPC-157 appears to normalize NO levels. In situations of NO deficiency (as occurs in ischemic tissue), it promotes NO production to restore blood flow.
This bidirectional modulation is unusual among therapeutic agents. Most NO-modulating drugs either increase or decrease NO. The ability to normalize in both directions, if it translates to humans, would be advantageous in Crohn's where both excessive mucosal NO (driving inflammation) and insufficient vascular NO (driving ischemia) coexist.
Dopamine System Interaction
BPC-157 has documented interactions with the dopaminergic system in animal studies. This may seem tangential to Crohn's, but the gut-brain axis is directly relevant to IBD. Dopamine receptors are expressed on intestinal immune cells and influence inflammatory responses in the gut. Stress-mediated dopamine dysregulation worsens Crohn's flares through autonomic effects on intestinal motility and mucosal blood flow.
Crohn's-Specific Evidence
TNBS Colitis Model (Grade C)
The TNBS (2,4,6-trinitrobenzenesulfonic acid) colitis model is the standard experimental model for Crohn's-type inflammation. Unlike the DSS (dextran sodium sulfate) model used for ulcerative colitis, TNBS produces transmural inflammation mediated by a Th1/Th17 immune response, mimicking the immunological profile of Crohn's disease.
Sikiric and colleagues tested BPC-157 in TNBS colitis across multiple studies. Results were consistent: BPC-157-treated animals showed reduced macroscopic and microscopic inflammation scores, accelerated mucosal regeneration, restored intestinal weight-to-length ratios, and improved colonic blood flow.
The doses used in animal studies (10 mcg/kg and 10 ng/kg, both intraperitoneally and orally) produced effects at both dose levels, suggesting a wide therapeutic window. The efficacy of oral administration is particularly relevant because BPC-157 is acid-stable, a property derived from its origin in gastric juice. This means oral dosing delivers the peptide directly to the inflamed intestinal mucosa without degradation.
Acetic Acid Colitis Model
BPC-157 also showed benefit in the acetic acid colitis model, which produces a chemical injury pattern. While less immunologically specific than the TNBS model, acetic acid colitis tests mucosal healing capacity directly. BPC-157 accelerated mucosal repair, reduced inflammatory cell infiltration, and restored tissue architecture compared to untreated controls.
Fistula Healing
Crohn's-related fistulas affect approximately 20 to 40 percent of Crohn's patients over their disease course. Perianal fistulas are the most common and most debilitating. Current treatment options include biologic therapy (infliximab has the strongest evidence for fistula closure), immunomodulators, seton placement, and surgical repair. Despite these interventions, fistula recurrence rates remain high.
Sikiric et al. demonstrated that BPC-157 accelerated fistula healing in animal models. The mechanism involves VEGF-mediated angiogenesis at the fistula tract, promoting granulation tissue formation and epithelialization. The tissue repair was organized rather than fibrotic, suggesting BPC-157 promotes functional healing rather than scar formation.
This is preclinical data. No human Crohn's fistula study exists for BPC-157. Fistulas are a serious complication that requires medical and often surgical management. BPC-157 should not be used as a substitute for established fistula treatments. The data is mentioned because it represents one of the most Crohn's-relevant findings in the BPC-157 literature.
NSAID Protection
Crohn's patients face a specific dilemma with NSAIDs. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) provide pain relief but can worsen IBD by disrupting the intestinal mucosal barrier. The mechanism involves inhibition of prostaglandin synthesis (specifically PGE2), which reduces mucosal blood flow and suppresses protective mucus secretion. Many gastroenterologists advise Crohn's patients to avoid NSAIDs entirely.
BPC-157 has demonstrated protection against NSAID-induced intestinal damage across multiple animal studies. It prevents the mucosal erosions, bleeding, and permeability increases that NSAIDs produce. This finding has practical relevance: Crohn's patients who need occasional NSAID use for joint pain (which accompanies Crohn's in 20 to 30 percent of cases through enteropathic arthritis) might theoretically be protected by concurrent BPC-157.
This is extrapolation from animal data. No human study has tested whether BPC-157 protects against NSAID-induced gut damage. But the data is consistent and mechanistically coherent.
Anastomotic Healing
Crohn's patients who undergo surgical resection (ileocecal resection is the most common Crohn's surgery) face risk of anastomotic leak and subsequent stricture formation at the surgical junction. BPC-157 has demonstrated accelerated anastomotic healing in animal surgical models, with improved tensile strength and reduced leak rates.
For Crohn's patients facing surgery, this is potentially relevant but entirely unproven in humans.
How BPC-157 Compares to Established Crohn's Treatments
BPC-157 should be understood in the context of treatments with actual human evidence. The Crohn's disease supplements guide covers the full evidence-graded landscape.
| Treatment | Evidence Grade | Human RCTs? | Mechanism | Notes |
|---|---|---|---|---|
| Anti-TNF biologics (infliximab) | A | Yes, extensive | TNF-alpha blockade | Standard of care for moderate-severe |
| Azathioprine/6-MP | A | Yes | Purine synthesis inhibition | Maintenance therapy |
| Budesonide | A | Yes | Corticosteroid (topical) | Induction of remission |
| Curcumin | B | Yes (adjunctive) | NF-kB, COX-2 inhibition | DINE-CD trial positive |
| Omega-3 | B | Yes (mixed) | Anti-inflammatory lipid mediators | Better for maintenance |
| Vitamin D | A (deficiency) | Yes | Immune modulation | Most Crohn's patients deficient |
| LDN | B | Yes (Phase 2) | Opioid growth factor axis | Smith 2007: 67% response |
| BPC-157 | C | No | VEGF, tight junctions, NO | Strong preclinical, zero clinical |
BPC-157 sits at the bottom of this hierarchy in terms of evidence. It sits near the top in terms of mechanistic relevance to Crohn's pathophysiology. The gap between preclinical promise and clinical validation is the fundamental problem with BPC-157 for Crohn's disease.
Drug Interactions with IBD Medications
No formal drug interaction study has been conducted for BPC-157 with any medication. The following is mechanistic analysis, not clinical data.
Anti-TNF Biologics (Infliximab, Adalimumab, Certolizumab)
Anti-TNF agents reduce inflammation by blocking tumor necrosis factor-alpha. BPC-157's mechanisms (angiogenesis, tight junction restoration, NO modulation) do not directly oppose TNF blockade. Theoretically, the two could be complementary: anti-TNF reduces the inflammatory signal while BPC-157 promotes tissue repair.
The concern is additive mucosal immune suppression. Anti-TNF biologics increase infection risk in the GI tract. Whether BPC-157's barrier-restoring effects would mitigate or complicate this risk is unknown.
Anti-Integrins (Vedolizumab)
Vedolizumab blocks alpha4-beta7 integrin, preventing lymphocyte trafficking to the gut. It is gut-selective, which reduces systemic immunosuppression. Adding oral BPC-157 to vedolizumab creates two gut-targeted agents operating simultaneously. The interaction is uncharacterized.
IL-12/23 Blockers (Ustekinumab)
Ustekinumab blocks the p40 subunit shared by IL-12 and IL-23, key cytokines in the Th1 and Th17 responses that drive Crohn's. BPC-157's mechanism does not directly intersect with IL-12/23 signaling. Theoretical risk of interaction is lower than with anti-TNF agents, but this is speculation.
Thiopurines (Azathioprine, 6-Mercaptopurine)
Thiopurines suppress purine synthesis in rapidly dividing immune cells. BPC-157 promotes cell proliferation for tissue repair. Whether these opposing effects on cell proliferation interact is unknown. The concern is theoretical but worth raising with your gastroenterologist.
5-ASA Medications (Mesalamine)
Mesalamine acts topically on the colonic mucosa to reduce inflammation through prostaglandin and leukotriene inhibition. BPC-157 also acts locally when taken orally. Both agents target mucosal inflammation through different mechanisms. Additive benefit is plausible. Adverse interaction is unlikely based on mechanism alone, but this has not been studied.
Corticosteroids (Prednisone, Budesonide)
Corticosteroids impair wound healing, a known clinical problem in Crohn's patients on long-term steroids who need surgery. BPC-157 promotes wound healing. In animal studies, BPC-157 has counteracted some of the tissue-damaging effects of corticosteroids. Whether this translates to a beneficial interaction in Crohn's patients on steroids is unknown.
Dosing for Crohn's Disease
All dosing is from practitioner protocols. No human dose-finding study exists for BPC-157 for any indication.
Oral (preferred for IBD): 250 to 500 mcg taken on an empty stomach, typically 30 minutes before breakfast. Some protocols split to twice daily (250 mcg morning and evening). BPC-157 is acid-stable and does not require enteric coating, which is relevant because Crohn's can affect the small intestine proximal to where enteric coatings dissolve.
Subcutaneous injection: 250 to 500 mcg once or twice daily. Some practitioners prefer injection for patients with severe small bowel Crohn's, reasoning that extensive mucosal damage may impair absorption of oral peptides. Injection also delivers BPC-157 systemically, which may be relevant for extraintestinal manifestations (joint disease, fistulas distant from the oral delivery route).
Duration: Practitioner protocols typically run 4 to 8 weeks, followed by 2 to 4 weeks off. Longer courses up to 12 weeks are sometimes used for severe cases. Cycling is recommended to prevent theoretical receptor desensitization.
Combination with other gut-healing compounds: Some protocols layer BPC-157 with L-glutamine (5 to 10 grams daily for enterocyte fuel) and zinc carnosine (75 mg twice daily for mucosal protection). L-glutamine has human evidence for gut permeability (Grade B). Adding evidence-based compounds alongside BPC-157 provides a stronger foundation than relying on the peptide alone.
What to monitor: Calprotectin (fecal inflammatory marker) is the most accessible objective measure of intestinal inflammation. CRP reflects systemic inflammation. Tracking these markers before, during, and after a BPC-157 trial provides objective data on whether the peptide is contributing to improvement beyond symptom perception.
Safety and Limitations
The Central Problem: No Human Trials
BPC-157 has been studied in more than 100 published animal experiments across dozens of tissue types and injury models. Zero randomized controlled trials in humans have been completed for any indication. The gap between preclinical volume and clinical validation is striking.
For Crohn's specifically, the TNBS colitis model is a reasonable approximation of human Crohn's pathophysiology. But models are not disease. The immune environment, microbiome composition, disease chronicity, and medication effects in human Crohn's are vastly more complex than any animal model captures.
WADA Ban and Regulatory Status
BPC-157 was banned by the World Anti-Doping Agency in 2022, classified as a prohibited growth factor. This does not mean it is dangerous. It means the angiogenic and tissue-repair effects could theoretically enhance athletic recovery. But the ban signals regulatory scrutiny.
BPC-157 is not FDA-approved for any indication. It is available through compounding pharmacies (prescription required) and research peptide suppliers. Quality varies between sources. Require a lot-specific certificate of analysis showing 98%+ purity from third-party HPLC testing.
Adverse Effects
No serious adverse effects have been reported in published animal studies at therapeutic doses. Practitioner and community reports describe BPC-157 as well-tolerated, with occasional mild GI discomfort (ironic for a gut-healing compound) and injection site irritation as the most common complaints.
Long-term safety data does not exist. The angiogenic mechanism raises a theoretical concern about promoting blood vessel growth in contexts where it is undesirable (existing tumors, for example). No evidence of tumor promotion has been reported, but no long-term oncology endpoint study has been conducted.
What BPC-157 Cannot Replace
BPC-157 is not a substitute for standard Crohn's disease management. Patients with moderate-to-severe Crohn's on biologic therapy, immunomodulators, or corticosteroids should not discontinue those treatments in favor of BPC-157. The evidence base for conventional Crohn's treatment includes hundreds of large RCTs. The evidence base for BPC-157 includes zero.
BPC-157 is best understood as a potential adjunct: a compound that may support mucosal healing alongside established treatments. Even in this role, compounds with actual human evidence (curcumin, omega-3, vitamin D, LDN) should be prioritized first. See the Crohn's disease supplements guide for the full evidence-graded protocol.
Building a Crohn's Gut Healing Protocol
For Crohn's patients considering BPC-157, here is where it fits in a rational, evidence-ordered protocol.
Tier 1: Evidence-based foundations. Vitamin D optimization to 40 to 60 ng/mL (Grade A for deficiency correction, which is present in most Crohn's patients). Omega-3 at 2 to 4 grams EPA+DHA daily (Grade B). L-glutamine at 5 to 10 grams daily (Grade B for gut permeability). Zinc carnosine at 75 mg twice daily (Grade B for mucosal protection).
Tier 2: Condition-specific interventions. Curcumin at 1 to 3 grams daily (Grade B, DINE-CD trial positive as adjunct). LDN at 4.5 mg nightly (Grade B for Crohn's, Smith 2007 Phase 2 trial). Autoimmune diet (AIP or Mediterranean, depending on tolerance).
Tier 3: Advanced and experimental. BPC-157 at 250 to 500 mcg oral (Grade C, strong preclinical). KPV peptide at 200 to 500 mcg oral (Grade C+, NF-kB mechanism). Fasting mimicking diet (Grade B for immune regeneration, Nature Medicine 2026 Crohn's RCT).
This hierarchy reflects the evidence, not enthusiasm. BPC-157 belongs in Tier 3 because it lacks human data. If Tiers 1 and 2 are optimized and symptoms persist, adding BPC-157 as an adjunct is a reasonable discussion with your gastroenterologist.
Frequently Asked Questions
Can BPC-157 help with Crohn's disease?
BPC-157 has shown consistent benefit in TNBS colitis models, which simulate Crohn's-type transmural inflammation. It promotes mucosal healing through angiogenesis, tight junction restoration, and nitric oxide modulation. However, no human clinical trial has been conducted for Crohn's or any form of IBD. This is Grade C evidence: the strongest preclinical gut-healing data of any peptide, but zero clinical proof.
Is BPC-157 safe for Crohn's patients on biologics?
No drug interaction study exists for BPC-157 with any biologic medication. BPC-157 promotes angiogenesis and tissue repair through mechanisms that do not directly oppose anti-TNF, anti-integrin, or anti-IL-12/23 biologics. Theoretical risk of adverse interaction is low based on mechanism analysis, but "low theoretical risk" is not "studied and safe." Discuss any peptide use with your gastroenterologist.
Should I take BPC-157 orally or by injection for Crohn's?
For intestinal Crohn's, oral administration delivers BPC-157 directly to inflamed mucosa. BPC-157 is acid-stable and survives gastric transit without enteric coating. Most IBD-focused practitioner protocols use oral dosing at 250 to 500 mcg on an empty stomach. Subcutaneous injection may be considered for extraintestinal complications (fistulas, joint involvement) or if severe small bowel damage is suspected to impair oral absorption.
How long does BPC-157 take to work for Crohn's?
Practitioner observations suggest initial symptom improvement within 2 to 4 weeks and more substantial changes in inflammatory markers (calprotectin, CRP) over 4 to 8 weeks. These timelines are from clinical experience, not controlled trials. Animal studies show accelerated mucosal healing within days, but animal models do not capture the chronicity and complexity of human Crohn's.
Can BPC-157 heal Crohn's fistulas?
Sikiric et al. demonstrated accelerated fistula healing in animal models with BPC-157, driven by VEGF-mediated angiogenesis and organized granulation tissue formation. No human fistula study exists. Crohn's fistulas are a serious complication requiring gastroenterological and often surgical management. BPC-157 should not replace infliximab (which has strong RCT evidence for fistula closure), seton drainage, or surgical repair. It might be considered as an adjunct under medical supervision.
Is BPC-157 FDA-approved for Crohn's disease?
No. BPC-157 is not FDA-approved for any indication. It was classified as a prohibited substance by WADA in 2022. It is available through compounding pharmacies (prescription required) and research peptide suppliers. The lack of FDA approval reflects the absence of human clinical trials, not a safety determination. For the broader context on peptides for autoimmune disease, including BPC-157's position relative to other compounds, see the peptide hub guide.
BPC-157 has the most extensive preclinical gut-healing evidence of any peptide. The TNBS colitis data, fistula healing results, NSAID protection, and anastomotic healing findings are consistently positive and mechanistically coherent. For Crohn's disease specifically, the match between BPC-157's repair mechanisms and Crohn's pathophysiology is closer than for almost any other experimental compound.
The problem is the word "experimental." Over 100 animal studies and zero human trials is a pattern that raises questions about why clinical translation has not occurred. The likely answer is commercial: as a naturally occurring peptide fragment, BPC-157 cannot be patented in its native form, removing the financial incentive for pharmaceutical companies to fund the expensive clinical trials needed for FDA approval.
For Crohn's patients, BPC-157 is worth knowing about and worth discussing with your gastroenterologist. It is not worth substituting for treatments that have actual clinical evidence. Build your protocol on the evidence-graded Crohn's supplement guide first. Consider BPC-157 as a Tier 3 addition after optimizing foundations.
Find out which interventions match your specific condition. Take the free AutoimmuneFinder quiz for a personalized, evidence-graded protocol.
This article is for educational purposes only and does not constitute medical advice. BPC-157 is not FDA-approved for any indication. No human clinical trial has been completed for Crohn's disease or any form of IBD. All dosing is from practitioner protocols; no human dose-finding study exists. Do not discontinue prescribed Crohn's medications in favor of BPC-157. Always consult your gastroenterologist before starting any new supplement or peptide protocol.